Key result
Hyperprolactinemia on antipsychotics is linked to higher ADP-stimulated platelet activation versus normoprolactinemic controls.
Why the study?
The molecular etiology underlying the increased risk of venous thromboembolism in patients on antipsychotic drugs is unknown, with hyperprolactinemia as a potential factor.
Does hyperprolactinemia in patients on antipsychotic drugs increase ADP-stimulated platelet activation?
Population
20 consecutive patients on antipsychotic drugs
Comparison
Hyperprolactinemic patients vs normoprolactinemic controls
Design
Observational pilot study
Authors
Loading...
May signal heightened VTE risk in antipsychotic users; hypothesis-generating and requires prospective validation before clinical adoption.
Observational (n=20)
Does hyperprolactinemia in patients on antipsychotic drugs increase ADP-stimulated platelet activation?
Hyperprolactinemia in patients taking antipsychotic drugs is associated with increased ADP-stimulated platelet activation, suggesting a potential mechanism for their increased risk of venous thromboembolism.
Wallaschofski et al. (2003) conducted an observational in Patients on antipsychotic drugs (n=20). Hyperprolactinemia vs. Normoprolactinemic controls was evaluated on ADP-stimulated and thrombin receptor activator 6-stimulated expression of the platelet activation marker P-selectin. Hyperprolactinemia in patients on antipsychotic drugs was associated with significantly higher ADP-stimulated platelet activation compared to normoprolactinemic controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: